Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351167 · ClinicalTrials.gov registry record · Phase 4
Genetically Informed Smoking Cessation Trial
A Phase 4 study of Smoking Cessation, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 822
- Enrollment target
- 1
- Study location
NCT02351167 is a Phase 4 study of Smoking Cessation that has completed, run by Washington University School of Medicine. The registered enrollment target is 822 participants, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (75% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02351167, a Phase 4 study of Smoking Cessation, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 822 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG Combination NRT (Nicotine patch, Nicotine lozenge)
- BEHAVIORAL Intensive smoking counseling
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2015-05-20 |
| Est. Completion | 2019-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02351167
The ClinicalTrials.gov registry entry for NCT02351167 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 822 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (75% higher). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02351167 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02351167 about?
NCT02351167 is a clinical study titled "Genetically Informed Smoking Cessation Trial". The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.
What is the current status of trial NCT02351167?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 822 participants. The study started on 2015-05-20. Estimated completion is 2019-08-31.
What conditions does trial NCT02351167 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT02351167?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Combination NRT (Nicotine patch, Nicotine lozenge) (DRUG), Intensive smoking counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT02351167?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02351167 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.